Expert Interview
Discussing the potential of CARVYKTI (ciltacabtagene autoleucel) and the results from the Phase 2 CARTITUDE-2 Cohort D study and the subgroup analysis from the CARTITUDE-4 study in multiple myeloma patients.
Ticker(s): LEGNInstitution: AZCC
- Double board-certified in medical oncology and internal medicine, and fellowship-trained in hematologic disorders and solid tumors
- Manages roughly 15 patients with multiple myeloma
- Has not prescribed Tecvayli but would consider it
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
